← All patient Q&A hubs

Top 10 Semaglutide Side-Effect Questions from Reddit, Answered

Last verified 2026-05-27 · 10 questions · 15 PubMed citations

This page pulls high-upvote patient questions from r/Semaglutide, r/WegovyWeightLoss, r/Ozempic about semaglutide and answers each with peer-reviewed trial data, FDA-label evidence, and current editorial analysis. Every answer cites at least one PubMed ID and links to the original Reddit source thread.

Question sources: r/Semaglutide, r/WegovyWeightLoss, r/Ozempic

Questions and answers

Will the nausea on semaglutide ever go away?

For most patients in the trials, nausea peaks during dose escalation and eases after a few weeks at a stable dose. In STEP 1, the pivotal 68-week trial of semaglutide 2.4 mg for obesity, nausea was the most common adverse event at 44% of treated patients versus 16% on placebo, but the events were predominantly mild to moderate and transient, occurring most often as doses were stepped up every 4 weeks (Wilding 2021, PMID 33567185). Across the SURMOUNT-style tolerability analyses of incretin therapy and in the STEP program itself, only about 4-7% of semaglutide patients stopped because of GI adverse events versus 2-3% on placebo, so most patients on the drug rode out the nausea rather than quitting. The standard label titration of 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg, with 4 weeks at each step, was designed specifically to limit nausea. If nausea is severe at a given step, many prescribers hold that dose for an extra 4 weeks instead of escalating on schedule. Severe persistent abdominal pain, repeated vomiting with dehydration, or signs of gallbladder disease are warning signs to call the prescriber rather than wait it out. None of this is medical advice.

Source thread ↗30 upvotes on RedditCites: PMID 33567185

Why am I getting sulfur burps on semaglutide?

Sulfur burps and delayed-onset reflux on semaglutide trace back to slowed gastric emptying. Semaglutide delays gastric emptying in the first hour after a meal by roughly 30%, which means food sits longer in the stomach before moving on (Hjerpsted 2018, PMID 28941314). When protein-heavy or high-fat foods linger, sulfur-containing amino acids (cysteine, methionine) can be broken down by gut bacteria into hydrogen sulfide, producing the rotten-egg taste that Reddit calls sulfur burps. Across the STEP trials, dyspepsia, eructation (burping) and GERD were reported more often on semaglutide than placebo, consistent with the slower transit (Wilding 2021, PMID 33567185). Patterns patients report: large evening meals, heavy red meat, eggs and cruciferous vegetables tend to trigger the worst episodes. Smaller meals, eating earlier in the evening, and not lying down right after a meal often help. If sulfur burps are accompanied by severe upper-abdominal pain that radiates to the back, that is a different pattern and may suggest pancreatitis or gallbladder disease, which warrants a prompt clinician call.

Source thread ↗35 upvotes on RedditCites: PMID 28941314, PMID 33567185

What helps with constipation on semaglutide?

Constipation on semaglutide is common, dose-related, and shows up in every major trial. In STEP 1, constipation was reported by about 24% of semaglutide patients versus 11% on placebo (Wilding 2021, PMID 33567185). The mechanism is mostly mechanical: slowed gastric emptying combined with lower food intake means less bulk and less water passing through the gut. The disproportionality pharmacovigilance analysis in JAMA found that GLP-1 receptor agonists raised the risk of bowel obstruction roughly fourfold versus bupropion-naltrexone, although absolute event rates remained low (Sodhi 2023, PMID 37796527). What patients report working in the threads usually maps onto standard constipation care: fluids of 80-100 oz a day, soluble fiber (psyllium or methylcellulose), magnesium glycinate or citrate at bedtime, and walking. Stimulant laxatives like senna are short-term tools rather than long-term answers. If constipation is severe, with no bowel movement for several days plus pain and vomiting, that is a sign to call the prescriber promptly to rule out obstruction. None of this is medical advice.

Source thread ↗67 upvotes on RedditCites: PMID 33567185, PMID 37796527

Does semaglutide really cause gallbladder problems?

Yes, and the data are pretty consistent. A 2022 systematic review and meta-analysis of 76 randomized trials covering more than 100,000 patients on GLP-1 receptor agonists found a 37% higher risk of gallbladder or biliary disease versus placebo or other comparators, with the highest risk at higher doses and longer treatment durations used for weight loss (He 2022, PMID 35344001). The most common events were cholelithiasis (gallstones) and cholecystitis. Rapid weight loss itself is a known trigger for gallstones, so part of the signal is shared between the drug and the weight loss it produces, and the FDA Wegovy label specifically warns about acute gallbladder disease. In STEP 1, gallbladder-related events occurred in 2.6% of semaglutide patients versus 1.2% on placebo (Wilding 2021, PMID 33567185). What that means in plain terms: most patients do not get a gallbladder problem, but the risk is real and elevated. Right-upper-quadrant pain after meals, especially fatty meals, plus nausea or fever, is the pattern to flag to a clinician promptly.

Source thread ↗112 upvotes on RedditCites: PMID 35344001, PMID 33567185

Will I lose muscle on semaglutide?

Some lean-mass loss is expected with any meaningful weight loss, and semaglutide is no exception. In a body-composition substudy of STEP 1 using DXA scans, patients who lost about 15% of body weight on semaglutide lost roughly 39% of that as lean mass and 61% as fat mass; because so much fat was lost, the proportion of fat mass in the body actually fell at the end of the study (Wilding 2021, PMID 33567185). That fat-to-lean ratio is broadly similar to what is seen in diet-only weight loss in older adults, and is one reason expert reviews emphasize protein intake and resistance training during GLP-1 treatment (Henney 2025, PMID 38710803). Standard counter-measures patients and clinicians lean on are evidence-based and inexpensive: aim for protein around 1.2-1.6 grams per kilogram of body weight per day, do resistance training 2-3 times per week, and avoid extended very-low-calorie days. People who eat low protein, do no resistance training, or lose weight very fast may lose a higher share of lean mass. None of this is medical advice; it summarizes the DXA substudy.

Source thread ↗174 upvotes on RedditCites: PMID 33567185, PMID 38710803

Is the hair loss on semaglutide permanent?

Most reports point to telogen effluvium, a temporary shedding pattern that follows rapid weight loss and resolves once the body stabilizes. Hair loss was not a labeled adverse event in STEP 1 at meaningful rates, but it appeared more often in later trials and in pharmacovigilance data: a FAERS disproportionality analysis of 2022-2023 reports found alopecia reporting odds ratios significantly elevated for semaglutide and tirzepatide compared with control drugs (Godfrey 2025, PMID 38925559). A 2025 systematic review of hair loss with GLP-1 receptor agonists concluded that the pattern was consistent with telogen effluvium, which is typically reversible once weight loss slows and nutritional intake stabilizes (Alsuwailem 2025, PMID 41111833). A separate VigiBase pharmacovigilance study also found hair-loss signals for semaglutide and other GLP-1 agents but emphasized that absolute risk per patient remained low (Nakhla 2025, PMID 39264502). Protein intake around 1.2-1.6 g/kg per day, adequate iron, zinc, vitamin D and B12, and slower weight-loss rate are the levers usually discussed. Persistent or patchy hair loss warrants a dermatology referral.

Source thread ↗11 upvotes on RedditCites: PMID 38925559, PMID 41111833, PMID 39264502

Why can I not sleep on semaglutide?

Insomnia is not one of the top labeled adverse events for semaglutide, but it shows up consistently in patient reports and in the broader STEP program safety data. In STEP 1, the safety profile reported nervous-system events including dizziness and headache more often on semaglutide than placebo, and several STEP trials list sleep-related events at low single-digit rates (Wilding 2021, PMID 33567185). Several plausible mechanisms have been proposed in published reviews: rapid weight loss itself can disrupt sleep architecture, lower food intake in the evening can trigger early-morning awakening, and the drug's effect on heart rate (a small mean increase of 1-3 beats per minute in STEP and SUSTAIN-6) may be perceptible in some people (Marso 2016, PMID 27633186). Patterns patients report as helpful: dose in the morning, finish the last meal at least 3 hours before bed, watch caffeine after noon, and keep some carbohydrate in the evening meal. If insomnia is severe or persistent beyond the first 4-8 weeks at a stable dose, discuss with the prescriber whether dose timing or a temporary dose hold is appropriate. None of this is medical advice.

Source thread ↗25 upvotes on RedditCites: PMID 33567185, PMID 27633186

Does semaglutide cause depression or suicidal thoughts?

The randomized trials and the largest cohort study do not show a signal for new depression or suicidality; the FAERS pharmacovigilance signals are mixed and disputed. In STEP 1, depression and suicidal-behavior events were rare and similar between semaglutide and placebo, and patients with active suicidal ideation were excluded at baseline (Wilding 2021, PMID 33567185). A 2024 real-world cohort study in Nature Medicine of more than 240,000 patients found that semaglutide was associated with a lower, not higher, risk of suicidal ideation versus non-GLP-1 weight-management or diabetes drugs (Wang 2024, PMID 38182782). However, FAERS and VigiBase pharmacovigilance analyses have reported disproportionate suicidality signals for GLP-1 agonists, prompting regulatory reviews (McIntyre 2024, PMID 38087976; McIntyre 2025, PMID 39433133). Mechanistically, the rapid weight loss, lower food intake and identity shifts during big body changes can affect mood without the drug being the direct cause. People with active major depression, eating-disorder history, or suicidality should discuss the risk-benefit with a prescriber and have a monitoring plan in place. None of this is medical advice.

Source thread ↗128 upvotes on RedditCites: PMID 33567185, PMID 38182782, PMID 38087976, PMID 39433133

Can semaglutide affect my eyes or vision?

Vision changes on semaglutide are mostly tied to rapid improvements in blood sugar in people who already have diabetes, not to the drug acting directly on the eye. In SUSTAIN-6, the cardiovascular outcomes trial of semaglutide in type 2 diabetes, retinopathy complications occurred in 3.0% of semaglutide patients versus 1.8% on placebo at 104 weeks, with the difference concentrated in patients who had pre-existing retinopathy and rapid HbA1c drops (Marso 2016, PMID 27633186). A pre-specified analysis confirmed that the elevated risk was largely explained by the magnitude and speed of glycemic improvement, a pattern also seen historically with insulin intensification (Vilsboll 2018, PMID 29178519). The FOCUS trial is the dedicated long-term study designed specifically to resolve the semaglutide-and-retinopathy question, and updated reviews continue to track its findings (Vujosevic 2025, PMID 40586870). In adults without diabetes, including the STEP weight-loss trials, retinopathy was not a flagged safety signal. Transient blurring on starting semaglutide can also reflect dehydration or rapid weight loss. Persistent blurry vision, new floaters, or eye pain warrant a prompt eye-doctor visit.

Source thread ↗31 upvotes on RedditCites: PMID 27633186, PMID 29178519, PMID 40586870

Why does my thyroid medication feel different on semaglutide?

Semaglutide slows gastric emptying, and that can change how oral medications dosed first thing in the morning are absorbed, including levothyroxine. The FDA label warns that semaglutide may impact the absorption of concomitantly administered oral medications because of delayed gastric emptying, and several published reviews flag levothyroxine specifically because it requires an empty stomach and a tight pharmacokinetic window to be absorbed reliably (Hall 2018, PMID 29915923). On top of that, meaningful weight loss itself changes thyroid hormone needs. In dedicated weight-loss studies, body weight reductions of 10% or more were associated with falling T3 and rising TSH on stable thyroid replacement, often requiring dose adjustment over time. STEP 1 documented an average 14.9% weight loss at 68 weeks on semaglutide 2.4 mg (Wilding 2021, PMID 33567185), and SUSTAIN-6 confirmed long-term cardiometabolic effects with no specific thyroid-disease signal in adults (Marso 2016, PMID 27633186). The practical takeaway patients on Reddit converge on is to recheck TSH 6-12 weeks after starting semaglutide and again after any meaningful weight change. None of this is medical advice.

Source thread ↗103 upvotes on RedditCites: PMID 29915923, PMID 33567185, PMID 27633186

Cited sources

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  2. 2.Marso SP, Bain SC, Consoli A, et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med. 2016. PMID: 27633186.
  3. 3.Hjerpsted JB, Flint A, Brooks A, et al Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity Diabetes Obes Metab. 2018. PMID: 28941314.
  4. 4.Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss JAMA. 2023. PMID: 37796527.
  5. 5.He L, Wang J, Ping F, et al Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials JAMA Intern Med. 2022. PMID: 35344001.
  6. 6.Henney AE, Wilding JPH, Alam U, Cuthbertson DJ Obesity pharmacotherapy in older adults: a narrative review of evidence Int J Obes (Lond). 2025. PMID: 38710803.
  7. 7.Godfrey H, Leibovit-Reiben Z, Jedlowski P, et al Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023 J Eur Acad Dermatol Venereol. 2025. PMID: 38925559.
  8. 8.Alsuwailem OA, Alanazi R, Almutairi HM, et al Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review Cureus. 2025. PMID: 41111833.
  9. 9.Nakhla M, Nair A, Balani P, et al Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study Cardiovasc Drugs Ther. 2025. PMID: 39264502.
  10. 10.Wang W, Volkow ND, Berger NA, et al Association of semaglutide with risk of suicidal ideation in a real-world cohort Nat Med. 2024. PMID: 38182782.
  11. 11.McIntyre RS, Mansur RB, Rosenblat JD, et al The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS) Expert Opin Drug Saf. 2024. PMID: 38087976.
  12. 12.McIntyre RS, Mansur RB, Rosenblat JD, et al Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase) J Affect Disord. 2025. PMID: 39433133.
  13. 13.Vilsboll T, Bain SC, Leiter LA, et al Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy Diabetes Obes Metab. 2018. PMID: 29178519.
  14. 14.Vujosevic S, Toma C, Ferrulli A, et al New generation agents for glycemic control and diabetic retinopathy progression: what we need to know? Acta Diabetol. 2025. PMID: 40586870.
  15. 15.Hall S, Isaacs D, Clements JN Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist Clin Pharmacokinet. 2018. PMID: 29915923.

Questions on this page are paraphrased from real patient discussions on the listed subreddits. Answers are editorial synthesis of peer-reviewed trial data, FDA labels, and our research desk’s analysis — not medical advice. Speak with your prescriber before changing any dose or regimen.

Browse all patient Q&A hubs, our Top-N PubMed lists, or our dose-ladder cheat sheets.